Akcea to license investigative antisense therapy AKCEA-ANGPTL3-LRx to Pfizer

This article was originally published here

Under the terms of the worldwide exclusive licensing agreement, Pfizer will pay an upfront license fee of $250m to Akcea and Ionis. The fee will be split equally

The post Akcea to license investigative antisense therapy AKCEA-ANGPTL3-LRx to Pfizer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply